Those responsible for the production of the Russian vaccine Sputnik V against the coronavirus have assured this Sunday that the price of the drug will be lower than that of its competitors Pfizer and Moderna. “Pfizer’s advertised price is $ 19.50 and Moderna’s is between $ 25 and $ 37 per dose, but it actually means a cost of $ 39 and $ 50 to $ 74 per person.”, they have explained in a message from their Twitter account picked up by the Russian news agency Sputnik.
Since “two doses per person are required for the Pfizer, Sputnik V and Moderna vaccines. The price of Sputnik V will be much lower ”, they have concluded in the message.
Hours before, the CEO of the American pharmaceutical company Moderna, Stéphane Bancel, had announced that the price of his product would range between 25 and 37 dollars a dose, according to commented to the ‘Welt am Sonntag’. “It is a fair price, given the burden that each serious case of COVID-19 places on the health system. For us it is not a question of profits ”, assured the executive, before clarifying that the final price will depend on the volume of each specific contract.
Bancel has added that Moderna intends to manufacture 20 million doses of vaccine in the remainder of the year and that “a small part” will be available for European countries already this year. “At the moment we have nothing signed but we are close to reaching an agreement with the European Commission. We want to provide Europe (with the vaccine) and we are conducting constructive negotiations ”, he revealed.
What stage is Sputnik V at? According to Denis Lugunov, director of the Gamaleya Center and member of the Russian Academy of Sciences who leads the group of developers of the Russian vaccine, 20 thousand people have received the first dose and 14 thousand people, go for the second: “Until we have the results of the research we cannot estimate what long-term effect the vaccine will have. We hope to have a long-lasting effect but we will know that in time.”.
“What we observed in the advances of our colleagues, since we had a conference where those from Pfizer, those from Oxford, Sinopharm were present, is that they all have the same principle: they are very similar and all producers reached Phase III synchronously , they are all very similar, but the key parameter stands out in which vaccine will be most effective. We will see that result in a very short time. Until we have the results, we cannot talk about the advantages of one independent vaccine over the other, ”Lugunov emphasized.
The pandemic forced scientists to experiment as the new disease occurs. That led to times accelerating. “No one knows how long immunity will last because we started this testing process four months ago. We have the experience of Ebola and MERS but we cannot take it as a parameter. At the end of the year we will be able to have the checkpoint since we will have reached six months ”, Lugunov pointed out.
As to new adverse effects that have been observed in this new stage, The professionals explained that they did not vary from the first phases: pain at the injection site, headache, fever, redness at the injection site, but there were no serious or moderate complications.
Artificially created, without any element of the coronavirus in its composition, the vaccine is presented in lyophilized form, that is, as a powder that is mixed with an excipient to dissolve it and then administered intramuscularly.
Sputnik V uses a human adenovirus technology of two different vectors, Ad5 and Ad26, for a first and a second injection. And its greatest endorsement was having been developed, in 2015, to treat Ebola, which passed all phases of clinical trials and was used to defeat the epidemic of that disease, in Africa, in 2017.
However, Sputnik V does not contain live human adenoviruses, but human adenoviral vectors that are not capable of multiplying and are advised to be safe for health. Other labs are also using human adenoviral vector-based platforms for their COVID-19 vaccines, such as Johnson & Johnson, which uses only the Ad26 vector, and China’s CanSino, which uses only Ad5.
The FDA approved the Regeneron treatment that Trump used to combat covid-19
The United Kingdom prepares a system of regional restrictions that will replace the lockdown from December
Why the arrival of a vaccine is just the beginning of the road to a new normal
*The article has been translated based on the content of Source link by https://www.infobae.com/america/mundo/2020/11/22/rusia-aseguro-que-su-vacuna-contra-el-coronavirus-sera-mas-barata-que-la-de-sus-competidores-pfizer-y-moderna/
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!